Treatment of a pituitary metastasis from a neuroendocrine tumour: Case report and literature review

Pituitary

Volumn 11, Issue 1, 2008, Pages 93-102

  Goglia, Umberto ^a   Ferone, Diego ^a   Sidoti, Marilena ^a   Spaziante, Renato ^a   Dadati, Patrizia ^b   Ravetti, Jean Luis ^b   Villa, Giuseppe ^b   Bodei, Lisa ^c   Paganelli, Giovanni ^c   Minuto, Francesco ^a   Giusti, Massimo ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

177Lu DOTATATE; 90Y DOTATOC; Neuroendocrine tumours; Octreotide; Pituitary mass

Indexed keywords

CABERGOLINE; CALCIUM CARBONATE; CHROMOGRANIN A; GLIMEPIRIDE; GONADOTROPIN; LEVOTHYROXINE; OCTREOTATE[1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LUTETIUM LU 177]; OCTREOTIDE; OCTREOTIDE[1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID YTTRIUM Y 90]; RADIOPHARMACEUTICAL AGENT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; AGED; ANGIOGRAPHY; ARTICLE; BRAIN BIOPSY; CANCER REGRESSION; CASE REPORT; DIABETES MELLITUS; DIPLOPIA; DRUG DOSE INCREASE; ECHOGRAPHY; FEMALE; HEADACHE; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS TUMOR; HYPOTHYROIDISM; IMMUNOHISTOCHEMISTRY; LIVER INJURY; LIVER METASTASIS; MULTIPLE CYCLE TREATMENT; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT RESPONSE; TUMOR VOLUME; VISUAL FIELD DEFECT;

ADENOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY; DELAYED-ACTION PREPARATIONS; DIAGNOSIS, DIFFERENTIAL; DIPLOPIA; FEMALE; HEADACHE; HUMANS; ILEAL NEOPLASMS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; PITUITARY NEOPLASMS; QUALITY OF LIFE; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; TIME FACTORS; TREATMENT OUTCOME;

EID: 38649104477     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-007-0038-6     Document Type: Article

References (32)

1. Komninos J, Vlassopoulou V, Protopapa D et al (2004) Tumors metastatic to the pituitary gland: Case report and literature review. J Clin Endocrinol Metab 89:574-580
2. Kaltsas GA, Besser GM, Grossman AB (2004) The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 25:458-511
3. Ferone D, Kwekkeboom DJ, Pivonello R et al (2001) In vivo and in vitro expression of somatostatin receptors in two human thymomas with similar clinical presentation and different histological features. J Endocrinol Invest 24:522-528
4. Ferone D, van Hagen MP, Kwekkeboom DJ et al (2000) Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro. J Clin Endocrinol Metab 85:1719-1726
5. Chiang MF, Brock M, Patt S (1990) Pituitary metastases. Neurochirurgia (Stuttg) 33:127-131
6. McCormick PC, Post KD, Kandji AD, Hays AP (1989) Metastatic carcinoma to the pituitary gland. Br J Neurosurg 3:71-79
7. Hanna FW, Williams OM, Davies JS, Dawson T, Neal J, Scanlon MF (1999) Pituitary apoplexy following metastasis of bronchogenic adenocarcinoma to a prolactinoma. Clin Endocrinol (Oxf) 51:377-381
8. Abe T, Matsumoto K, Iida M, Hayashi M, Sanno N, Osamura RY (1997) Malignant carcinoid of the anterior mediastinum metastasis to a prolactin-secreting pituitary adenoma: A case report. Surg Neurol 48:389-394
9. Sanno N, Teramoto A, Osamura RY, Genka S, Katakami H et al (1997) A growth hormone-releasing hormone-producing pancreatic islet cell tumor metastasized to the pituitary is associated with pituitary somatotroph hyperplasia and acromegaly. J Clin Endocrinol Metab 82:2731-2737
10. Gernez-Lestradet C, Buchet S, Ranfaing J, Mollet E (1991) Pituitary metastasis from small-cell bronchial carcinoma with hyperprolactinemia. Presse Med 20:223
11. Tchenio X, Mornex F, Sassolas G, Cordier JF (2000) Symptomatic hypothalamo-hypophyseal metastasis revealing a small-cell bronchial carcinoma. Study of two cases. Rev Mal Respir 17:1107-1109
12. Hopster DJ, Robinson SF, Chadwick L, Geddes JF (1997) Widespread neuroendocrine malignancy within the central nervous system: A diagnostic conundrum. J Clin Pathol 50:440-442
13. Danikas D, Theodorou SJ, Matthews WE, Rienzo AA (2000) Unusually aggressive rectal carcinoid metastasizing to larynx, pancreas, adrenal glands and brain. Am Surg 66:1179-1180
14. Castro Cabezas M, Vrinten DH, Burgers JA, Croughs RJM (1998) Central diabetes insipidus and Cushing's syndrome due to ectopic ACTH production by disseminated small cell lung cancer: A case report. Neth J Med 53:32-36
15. Shimon I, Hadani M, Nass D, Zwas ST (2004) Malignant bronchial carcinoid tumor metastatic to the pituitary in a thyroid carcinoma patient: successful treatment with surgery, radiotherapy and somatostatin analog. Pituitary 7:51-57
16. Molinatti Pia A, Scheithauer Bernd W, Randall Raymond V, Laws Edward R Jr (1985) Metastasis to pituitary adenoma. Arch Pathol Lab Med 109:287-289
17. Rossi ML, Bevan JS, Fleming KA, Cruz-Sanchez F (1988) Pituitary metastasis from malignant bronchial carcinoid. Tumori 74:101-105
18. Schubiger O, Haller D (1992) Metastases to the pituitary-hypothalamic axis: An MR study of 7 symptomatic patients. Neuroradiology 34:131-134
19. Max MB, Deck MB, Rottemberg DA (1981) Pituitary metastasis: Incidence in cancer patients and clinical differentiation from pituitary adenoma. Neurology 31:998-1002
20. Giusti M, Sidoti M, Augeri S, Rabitti C, Minuto F (2004) Effect of short term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. Eur J Endocrinol 150:299-303
21. Hofland LJ, Lamberts SW (2003) The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 24:28-47
22. Schonbrunn A (1982) Glucocorticoids down-regulate somatostatin receptors on pituitary cells in culture. Endocrinology 110:1147-1154
23. Fjallskog ML, Ludvigsen E, Stridsberg M, Oberg K, Eriksson B, Janson ET (2003) Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors. Med Oncol 20:59-67
24. Mundschenk J, Unger N, Schulz S, Hollt V, Schulz S, Steinke R, Lehnert H (2003) Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. J Clin Endocrinol Metab 88:5150-5157
25. Kolby L, Wängberg B, Ahlman H, Tisell L-E, Fjälling M, Forssell-Aronsson E, Nilsson O (1998) Somatostatin receptor subtypes, octreotide scintigraphy, and clinical response to octreotide treatment in patients with neuroendocrine tumors. World J Surg 22:679-683
26. Ruelle A, Palladino M, Andrioli GC (1992) Pituitary metastases as presenting lesions of malignancy. J Neurosurg Sci 36:51-54
27. Kaltsas GA, Besser GM, Grossman AB (2004) The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 25:458-511
28. Jensen RT (2000) Carcinoid and pancreatic endocrine tumors: Recent advances in molecular pathogenesis, localization, and treatment. Curr Opin Oncol 12:368-377
29. Bodei L, Cremonesi M, Grana C et al (2004) Receptor radionuclide therapy with 90 Y-[DOTA 0] -Tyr 3 -octreotide (90 Y-DOTATOC) in neuroendocrine tumors. Eur J Nucl Med Mol Imaging 31:1038-1046
30. De Jong M, Valkema R, Jmar F et al (2002) Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings. Semin Nucl Med 32:133-140
31. Waldherr C, Pless M, Maecke HR et al (2002) Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90) Y-DOTATOC. J Nucl Med 43:610-616
32. Kwekkeboom DJ, Teunissen JJ, Bakker WH et al (2005) Radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr 3] octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 23:2754-2762